Latest Breaking News On - John mascarenhas - Page 4 : comparemela.com

Dr Mascarenhas on the Goals of the Phase 1/2 KRT-232-109 Study in Myelofibrosis

Dr Mascarenhas on the Goals of the Phase 1/2 KRT-232-109 Study in Myelofibrosis
onclive.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from onclive.com Daily Mail and Mail on Sunday newspapers.

John mascarenhasIcahn school of medicineTisch cancer instituteIcahn schoolMount sinaiBlood cancersMyeloid disorders

Dr Mascarenhas on the Rationale for the KRT-232-109 Study in Secondary Myelofibrosis

John Mascarenhas, MD, discusses the rationale for adding the first-in-class MDM2 inhibitor navtemadlin to ruxolitinib in patients receiving treatment for primary or secondary myelofibrosis who have previously had suboptimal responses with ruxolitinib.

John mascarenhasIcahn school of medicineTisch cancer instituteIcahn schoolMount sinaiBlood cancersMyeloid disordersThe tisch cancer institute at mount sinaiOnclive tvMyeloproliferative neoplasms

Sobi KOL investor event: the journey for Vonjo®

Sobi KOL investor event: the journey for Vonjo® 14 July, 2023 17:15 19 July 2023 15:30 CEST, 14:30 BST, 09:30.

United statesUnited kingdomSarah buckleyJohn mascarenhasHead of clinical affairsSobi investor relations teamIcahn school of medicine at mount sinaiClinical affairsKey opinion leaderIcahn schoolMount sinaiNorth americaMiddle eastFor sobi media

Karyopharm Therapeutics (KPTI) Initiates Pivotal Phase 3 Study of XPO1 Inhibitor Selinexor and Ruxolitinib in JAK Inhibitor (JAKi) Naïve Myelofibrosis

Karyopharm Therapeutics (KPTI) Initiates Pivotal Phase 3 Study of XPO1 Inhibitor Selinexor and Ruxolitinib in JAK Inhibitor (JAKi) Naïve Myelofibrosis
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United statesJohn mascarenhasReshma rangwalaAmerican society of clinical oncologyIcahn school of medicine at mount sinaiAmerican association for cancer researchEuropean hematology associationKaryopharm therapeutics incKaryopharm therapeuticsChief medical officerIcahn schoolMount sinaiBlood cancersAmerican associationCancer researchAnnual meeting

MorphoSys to Host Virtual Investor Call with Key Opinion Leaders Focused on Pelabresib on June 21,

EQS-News: MorphoSys AG / Key word(s): Miscellaneous MorphoSys to Host Virtual Investor Call with Key Opinion Leaders Focused on Pelabresib on June 21, 2023 14.06.2023 / 08:39 CET/CESTThe issuer is solely responsible for the content of this announcement.Media ReleasePlanegg/Munich, Germany, June 14, 2023 MorphoS.

United statesNew yorkTim demuthJean paul kressJulia neugebauerGabriela hobbsJohn mascarenhasEamonn nolanThomas biegiDistribution servicesTisch cancer institute at mount sinaiConstellation pharmaceuticals incProfessor of medicine at harvard medical schoolAdult leukemia programExchange commissionLeukemia service at massachusetts